| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Tech Ops Officer
1 company
Bilal Arif last filed a Form 4 in October 2025, as Chief Tech Ops Officer at SRPT. Bilal Arif's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Bilal Arif's trades have earned a strong insider score of 77/100 across 3 rated trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +64.8%.
At the last filing, the largest reported position was 32,500 shares of SRPT. The SRPT filings lean toward selling, a net 13,757 shares.
Bilal Arif has 17 Form 4 filings on record from December 2022 to October 2025, across 2 companies: Chief Operations Officer at KalVista Pharmaceuticals (KALV), 2025; Chief Tech Ops Officer at Sarepta Therapeutics (SRPT), 2022–2025.
The 41 reported transactions were 20 tax withholdings, 8 option or other derivative awards, 8 open-market sales and 3 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $2.2M.
The largest open-market sale was 11,757 shares of SRPT at an average $163.13 on June 25, 2024, about $1.9M. Twelve months later SRPT was down 89%.
1 of the 2 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other was not.
Shares as reported in the last Form 4 for each company; the most recent is from October 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.